Equities

Panacea Biotec Ltd

PANACEABIO:NSI

Panacea Biotec Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)143.13
  • Today's Change9.90 / 7.43%
  • Shares traded1.19m
  • 1 Year change+13.15%
  • Beta1.0151
Data delayed at least 15 minutes, as of Jul 04 2024 11:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.

  • Revenue in INR (TTM)5.59bn
  • Net income in INR-9.40m
  • Incorporated1984
  • Employees1.09k
  • Location
    Panacea Biotec LtdB-1 Extn / G-3Mathura Road, Mohan Co-opIndlEstateNEW DELHI 110044IndiaIND
  • Phone+91 1 141679000
  • Fax+91 1 141679075
  • Websitehttps://www.panaceabiotec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wanbury Ltd5.76bn559.56m5.39bn1.58k9.6319.297.810.936317.0917.09175.718.531.7810.437.27--17.3011.6399.14--47.4343.799.727.620.57571.950.8065--15.218.02638.26--29.87--
Kilitch Drugs (India) Ltd1.54bn146.02m5.54bn153.0037.553.1432.723.599.179.1797.14109.620.671830.802.63--5.913.388.274.7639.8136.088.796.172.213.510.153--10.5813.3539.7530.69-19.45--
ZIM Laboratories Ltd3.67bn172.46m5.60bn556.0032.522.3516.881.533.543.5475.3449.000.93212.543.766,608,353.004.383.886.666.5453.3447.454.693.970.91823.670.31891.21-7.801.84-29.422.3729.41--
Medicamen Biotech Ltd1.79bn109.31m6.49bn388.0062.953.2439.153.628.118.11135.05157.680.62581.772.98--3.315.894.758.4948.3639.065.299.581.103.440.13328.4627.297.90-26.36-1.89-16.710.00
Nectar Lifesciences Ltd16.86bn49.95m7.05bn1.59k136.610.65910.720.4180.230.2379.1647.680.76971.745.12--0.228-0.29560.3969-0.54128.6818.390.2963-0.40520.59071.060.3728--10.63-9.54120.65-36.29-5.06--
Sakar Healthcare Ltd1.53bn116.71m7.09bn297.0058.562.7023.884.635.575.5773.21120.610.4233.887.13--3.225.263.816.2845.4344.137.6010.120.7432.680.2322--14.9917.58-8.5311.7619.05--
Albert David Ltd3.62bn754.20m7.57bn1.27k10.031.989.202.09132.16132.16635.16671.050.78682.6712.15--16.3710.0020.8513.1565.3061.0320.8111.873.31124.700.008612.896.122.72108.4933.5940.8713.90
IND Swift Laboratories Ltd12.81bn3.07bn7.88bn1.50k2.570.84632.180.615451.9951.99216.90157.640.8573.453.80--20.585.0025.676.1339.4742.8224.028.522.941.700.0175--6.1011.10784.4470.8223.60--
Panacea Biotec Ltd5.59bn-9.40m8.16bn1.09k--0.969123.181.46-0.16-0.1691.52137.480.44521.219.52---0.119410.26-0.159716.5358.8552.88-0.268324.870.9948-15.860.0244--21.574.1396.48--74.65--
Jagsonpal Pharmaceuticals Ltd2.09bn224.63m9.00bn940.0040.164.8037.304.318.478.4778.3170.881.015.2713.12--10.9010.9512.3013.2955.0058.1710.769.219.6326.290.045543.81-11.834.58-15.9425.50-35.6982.06
Bajaj Healthcare Ltd4.73bn-143.27m9.39bn1.06k--3.3770.651.98-5.18-30.36171.62100.860.56811.442.32---1.726.97-3.5112.7346.1830.16-3.037.200.80961.640.54465.38-29.695.04-133.30--15.08--
JG Chemicals Ltd6.68bn308.56m9.98bn112.0029.842.5027.241.498.548.54185.73101.67----------------14.64--4.81--8.5745.210.0329---14.90---43.84------
Bliss GVS Pharma Ltd7.70bn754.54m10.84bn763.0014.591.1210.041.417.087.0872.8692.390.64983.451.95--6.886.468.378.2250.3944.2110.599.924.3417.970.09057.932.48-3.036.49-9.42-8.33-12.94
Data as of Jul 04 2024. Currency figures normalised to Panacea Biotec Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Motilal Oswal Asset Management Co. Ltd.as of 31 May 2024157.000.00%
Data from 15 Jun 2024 - 15 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.